You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 5,670,514


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,670,514
Title: Compositions for inhibiting bone loss
Abstract:The present invention provides methods of inhibiting bone loss in mammals via the administration to a mammal in need of such treatment an effective amount of a compound from a series of benzoquinolin-3-ones. Such compounds also are sequentially or concurrently coadministered with a bone antiresorptive agent or a bone anabolic agent.
Inventor(s): Audia; James E. (Indianapolis, IN), Neubauer; Blake L. (Indianapolis, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:08/625,567
Patent Claims:1. A pharmaceutical composition comprising a compound of formula I ##STR13## wherein R and R.sup.1 both represent hydrogen or combine to form a bond;

R.sup.2 represents hydrogen or C.sub.1 -C.sub.3 alkyl;

R.sup.3 represents hydrogen, methyl or ethyl; either R.sup.4 and X--R.sup.5 have the following definitions, (R.sup.6).sub.m is absent, and R.sup.3 does not represent hydrogen; or (R.sup.6).sub.m has the following definition, R.sup.4 and X--R.sup.5 are absent, and R.sup.3 does not represent ethyl;

R.sup.4 and --X--R.sup.5 each occupies one of the 7-, 8- and 9-positions;

R.sup.4 represents hydrogen, halo, methyl or ethyl;

X represents C.sub.1 -C.sub.4 alkyl, C.sub.2 -C.sub.4 alkenyl, C.sub.2 -C.sub.4 alkynyl, a bond --SO--, --SO.sub.2 --, --CO--Y--(CH.sub.2).sub.n --, --Y--CO--(CH.sub.2).sub.n, --CO--, --Z--(CH.sub.2).sub.n --, or --SO.sub.3 --; wherein X groups which are not symmetrical may be in either orientation;

Y represents --S--, --O--, or --NH--;

Z represents --O-- or --S--;

n represents 0-3;

R.sup.5 represents phenyl, naphthalenyl, pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, anthracenyl, acenaphthalenyl, thiazolyl, benzimidazolyl, indazolyl, thiophenyl, phenanthrenyl, quinolinyl, fluorenyl, isoquinolinyl, indanyl, benzopyranyl, indolyl, benzisoquinolinyl, benzindolyl, benzothiazolyl, benzothiophenyl, quinoxalinyl, benzoxazolyl, tetrazolyl, naphthothiazolyl, quinazolinyl, thiazolopyridinyl, pyridazinoquinazolinyl, benzisothiazolyl, benzodioxolyl, benzodioxinyl, diphenylmethyl or triphenylmethyl;

the above R.sup.5 groups are unsubstituted or substituted with 1-3 groups chosen from the group consisting of halo, trifluoromethyl, trifluoroethoxy, C.sub.1 -C.sub.4 alkyl, trifluoromethoxy, hydroxy, C.sub.1 -C.sub.3 alkoxy, nitro, C.sub.1 -C.sub.3 alkylthio, C.sub.1 -C.sub.6 alkanoyl, phenyl, oxo, phenoxy, phenylthio, C.sub.1 -C.sub.3 alkylsulfinyl, C.sub.1 -C.sub.3 alkylsulfonyl, cyano, amino, C.sub.1 -C.sub.3 alkylamino, diphenylmethylamino, triphenylmethylamino, benzyloxy, benzylthio, (mono-halo, nitro or CF.sub.3)benzyl(oxy or thio), di(C.sub.1 -C.sub.3 alkyl, C.sub.3 -C.sub.6 cycloalkyl, or C.sub.4 -C.sub.8 cycloalkylalkyl)amino, (mono-C.sub.1 -C.sub.3 alkyl, C.sub.1 -C.sub.3 alkoxy or halo)-(phenyl, phenoxy, phenylthio, phenylsulfonyl or phenoxysulfonyl), C.sub.2 -C.sub.6 alkanoylamino, benzoylamino, diphenylmethylamino(C.sub.1 -C.sub.3 alkyl), aminocarbonyl, C.sub.1 -C.sub.3 alkylaminocarbonyl, di(C.sub.1 -C.sub.3 alkyl)aminocarbonyl, halo-C.sub.1 -C.sub.6 alkanoyl, aminosulfonyl, C.sub.1 -C.sub.3 alkylaminosulfonyl, di(C.sub.1 -C.sub.3 alkyl)aminosulfonyl, phenyl(oxy or thio) (C.sub.1 -C.sub.3 alkyl), (halo, C.sub.1 -C.sub.3 alkyl or C.sub.1 -C.sub.3 alkoxy)phenyl(oxy or thio) (C.sub.1 -C.sub.3 alkyl), benzoyl, or (amino, C.sub.1 -C.sub.3 alkylamino or di(C.sub.1 -C.sub.3 alkyl)amino) (C.sub.1 -C.sub.3 alkyl);

or an above R.sup.5 group is substituted with a morpholino(C.sub.1 -C.sub.3 alkyl) group, a phenyl(C.sub.1 -C.sub.3 alkyl)piperidinyl group, a phenyl(C.sub.1 -C.sub.3 alkyl)-piperidinylaminocarbonyl group, a C.sub.2 -C.sub.6 alkanoyl-aminothiophenyl group, or a (amino, C.sub.1 -C.sub.3 alkylamino or di(C.sub.1 -C.sub.3 alkyl)amino)naphthalenylsulfonylamino group;

or R.sup.5 is a perhalophenyl group;

m represents 1-2;

R.sup.6 represents hydrogen, halogen, NO.sub.2, cyano, CF.sub.3, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, carboxy, C.sub.1 -C.sub.6 alkoxycarbonyl, amino, C.sub.1 -C.sub.4 alkylamino, C.sub.1 -C.sub.4 dialkylamino, amido, C.sub.1 -C.sub.4 alkylamido, C.sub.1 -C.sub.4 dialkylamido, mercapto, C.sub.1 -C.sub.6 alkylthio, C.sub.1 -C.sub.6 alkylsulfinyl, C.sub.1 -C.sub.6 alkylsulfonyl, or a group --A--R.sup.7 where A is C.sub.1 -C.sub.6 alkylene C.sub.2 -C.sub.6 alkenylene or C.sub.2 -C.sub.6 alkynylene; and R.sup.7 represents halogen, hydroxy, CF.sub.3, C.sub.1 -C.sub.6 alkoxy, carboxy, C.sub.1 -C.sub.6 alkoxycarbonyl, amino, C.sub.1 -C.sub.4 alkylamino, C.sub.1 -C.sub.4 dialkylamino, amido, C.sub.1 -C.sub.4 alkylamido, C.sub.1 -C.sub.4 dialkylamido, C.sub.1 -C.sub.4 alkylsulfonylamino, aminosulfonyl or C.sub.1 -C.sub.4 alkylaminosulfonyl;

or a pharmaceutically acceptable salt thereof, and an effective amount of a bone antiresorptive agent, in combination with a pharmaceutically acceptable carrier, diluent, or excipient.

2. A pharmaceutical composition according to claim 1 wherein said bone antiresorptive agent is estrogen, raloxifene, or alendronate.

3. A pharmaceutical composition comprising a compound of formula I ##STR14## wherein R and R.sup.1 both represent hydrogen or combine to form a bond;

R.sup.2 represents hydrogen or C.sub.1 -C.sub.3 alkyl;

R.sup.3 represents hydrogen, methyl or ethyl; either R.sup.4 and X--R.sup.5 have the following definitions, (R.sup.6).sub.m is absent, and R.sup.3 does not represent hydrogen; or (R.sup.6).sub.m has the following definition, R.sup.4 and X--R.sup.5 are absent, and R.sup.3 does not represent ethyl;

R.sup.4 and --X--R.sup.5 each occupies one of the 7-, 8- and 9-positions;

R.sup.4 represents hydrogen, halo, methyl or ethyl;

X represents C.sub.1 -C.sub.4 alkyl, C.sub.2 -C.sub.4 alkenyl, C.sub.2 -C.sub.4 alkynyl, a bond, --SO--, --SO.sub.2 --, --CO--Y--(CH.sub.2).sub.n, --Y--CO--(CH.sub.2).sub.n, --CO--, --Z --(CH.sub.2).sub.n --, or --SO.sub.3 --; wherein X groups which are not symmetrical may be in either orientation;

Y represents --S--, --O--, or --NH--;

Z represents --O--or --S--;

n represents 0-3;

R.sup.5 represents phenyl, naphthalenyl, pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, anthracenyl, acenaphthalenyl, thiazolyl, benzimidazolyl, indazolyl, thiophenyl, phenanthrenyl, quinolinyl, fluorenyl, isoquinolinyl, indanyl, benzopyranyl, indolyl, benzisoquinolinyl, benzindolyl, benzothiazolyl, benzothiophenyl, quinoxalinyl, benzoxazolyl, tetrazolyl, naphthothiazolyl, quinazolinyl, thiazolopyridinyl, pyridazinoquinazolinyl, benzisothiazolyl, benzodioxolyl, benzodioxinyl, diphenylmethyl or triphenylmethyl;

the above R.sup.5 groups are unsubstituted or substituted with 1-3 groups chosen from the group consisting of halo, trifluoromethyl, trifluoroethoxy, C.sub.1 -C.sub.4 alkyl, trifluoromethoxy, hydroxy, C.sub.1 -C.sub.3 alkoxy, nitro, C.sub.1 -C.sub.3 alkylthio, C.sub.1 -C.sub.6 alkanoyl, phenyl, oxo, phenoxy, phenylthio, C.sub.1 -C.sub.3 alkylsulfinyl, C.sub.1 -C.sub.3 alkylsulfonyl, cyano, amino, C.sub.1 -C.sub.3 alkylamino, diphenylmethylamino, triphenylmethylamino, benzyloxy, benzylthio, (mono-halo, nitro or CF.sub.3)benzyl(oxy or thio), di(C.sub.1 -C.sub.3 alkyl, C.sub.3 -C.sub.6 cycloalkyl, or C.sub.4 -C.sub.8 cycloalkylalkyl)amino, (mono-C.sub.1 -C.sub.3 alkyl, C.sub.1 -C.sub.3 alkoxy or halo)-(phenyl, phenoxy, phenylthio, phenylsulfonyl or phenoxysulfonyl), C.sub.2 -C.sub.6 alkanoylamino, benzoylamino, diphenylmethylamino(C.sub.1 -C.sub.3 alkyl), aminocarbonyl, C.sub.1 -C.sub.3 alkylaminocarbonyl, di(C.sub.1 -C.sub.3 alkyl)aminocarbonyl, halo-C.sub.1 -C.sub.6 alkanoyl, aminosulfonyl, C.sub.1 -C.sub.3 alkylaminosulfonyl, di(C.sub.1 -C.sub.3 alkyl)aminosulfonyl, phenyl(oxy or thio) (C.sub.1 -C.sub.3 alkyl), (halo, C.sub.1 -C.sub.3 alkyl or C.sub.1 -C.sub.3 alkoxy)phenyl(oxy or thio) (C.sub.1 -C.sub.3 alkyl), benzoyl, or (amino, C.sub.1 -C.sub.3 alkylamino or di(C.sub.1 -C.sub.3 alkyl)amino) (C.sub.1 -C.sub.3 alkyl);

or an above R.sup.5 group is substituted with a morpholino (C.sub.1 -C.sub.3 alkyl) group, a phenyl (C.sub.1 -C.sub.3 alkyl)piperidinyl group, a phenyl (C.sub.1 -C.sub.3 alkyl)-piperidinylaminocarbonyl group, a C.sub.2 -C.sub.6 alkanoyl-aminothiophenyl group, or a (amino, C.sub.1 -C.sub.3 alkylamino or di(C-C.sub.3 alkyl)amino)naphthalenylsulfonylamino group;

or R.sup.5 is a perhalophenyl group;

m represents 1-2;

R.sup.6 represents hydrogen, halogen, NO.sub.2, cyano, CF.sub.3, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, carboxy, C.sub.1 -C.sub.6 alkoxycarbonyl, amino, C.sub.1 -C.sub.4 alkylamino, C.sub.1 -C.sub.4 dialkylamino, amido, C.sub.1 -C.sub.4 alkylamido, C.sub.1 -C.sub.4 dialkylamido, mercapto, C.sub.1 -C.sub.6 alkylthio, C.sub.1 -C.sub.6 alkylsulfinyl, C.sub.1 -C.sub.6 alkylsulfonyl, or a group --A--R.sup.7 where A is C.sub.1 -C.sub.6 alkylene C.sub.2 -C.sub.6 C.sub.6 alkenylene or C.sub.2 -C.sub.6 alkynylene; and R.sup.7 represents halogen, hydroxy, CF.sub.3, C.sub.1 -C.sub.6 alkoxy, carboxy, C.sub.1 -C.sub.6 alkoxycarbonyl, amino, C.sub.1 -C.sub.4 alkylamino, C.sub.1 -C.sub.4 dialkylamino, amido, C.sub.1 -C.sub.4 alkylamido, C.sub.1 -C.sub.4 dialkylamido, C.sub.1 -C.sub.4 alkylsulfonylamino, aminosulfonyl or C.sub.1 -C.sub.4 alkylaminosulfonyl;

or a pharmaceutically acceptable salt thereof, and an effective amount of a bone anabolic agent, in combination with a pharmaceutically acceptable carrier, diluent, or excipient.

4. A pharmaceutical composition according to claim 3 wherein said bone anabolic agent is parathyroid hormone (1-84) or (1-34).

5. A pharmaceutical composition comprising (-)-(4aR)-(10bR)-8-chloro-4-methyl-1,2,3,4,4a,5,6,10b-octahydrobenzo[f]-qu inolin-3-one, or a pharmaceutically acceptable salt thereof, and raloxifene or a pharmaceutically acceptable sale thereof, in combination with a pharmaceutically acceptable carrier, diluent or excipient.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.